Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Seong Jin Jo, Chul-Jong Park, Chul Hwan Bang, Ki-Heon Jeong, Bong Seok Shin, Dong Hyun Kim, Hae Jun Song, Ju-Hee Lee, YoungEun Kim, Sun Choi, Sang Woong Youn
Small plaque psoriasis is the typical form of chronic plaque psoriasis affecting adults in South Korea. The effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) aerosol foam for large and small psoriasis plaques has not previously been examined. We performed a post hoc analysis of a recent, 4-week observational study of Cal/BD aerosol foam use in routine clinical practice in South Korea. Investigator Global Assessment response ([IGA] 0/1 at week 4), Patient Global Assessment response ([PaGA] 0/1 at week 4), change in Psoriasis Area and Severity Index (PASI), changes in psoriasis symptom scores, change in the Dermatology Life Quality Index (DLQI), and the proportion of patients achieving DLQI ≤5 were analyzed for patients with small (≤5 cm; n = 131) or large (>5 cm; n = 35) baseline plaque size...
May 8, 2024: Journal of Dermatology
#2
JOURNAL ARTICLE
Fenglian Yan, Lin Wang, Junfeng Zhang, Zhihong Liu, Bin Yu, Wenbo Li, Zhengran Guo, Dongmei Shi, Hui Zhang, Huabao Xiong
Psoriasis is a chronic inflammatory skin disease substantially affecting the quality of life, with no complete cure owing to its complex pathogenesis. Cornuside, a major bioactive compound present in Cornus officinalis Sieb. et Zucc., which is a well-known traditional Chinese medicine with a variety of biological and pharmacological activities, such as anti-apoptotic, antioxidant, and anti-inflammatory properties. However, its effects on psoriasis remain unclear. Our preliminary analysis of network pharmacology showed that cornuside may be involved in psoriasis by regulating the inflammatory response and IL-17 signaling pathway...
May 4, 2024: International Immunopharmacology
#3
JOURNAL ARTICLE
Sandra L Brandi, Lone Skov, Katrine Strandberg-Larsen, Claus Zachariae, Luise Cederkvist, Jonathan Groot, Anne-Marie Nybo Andersen
BACKGROUND: Psoriasis is a chronic skin disease associated with lower quality of life and higher risk of anxiety and depression in adults. We investigate whether adolescents with psoriasis also experience poorer mental health than their peers. METHODS: In this cross-sectional study, we included questionnaire data on psoriasis and mental health from the 18-year follow-up of the Danish National Birth Cohort. We estimated odds ratios (OR) and 95 % confidence intervals (CI) using a logistic regression with inverse probability weighting to account for potential selection bias, adjusted for potential confounders identified a priori...
May 2, 2024: Journal of Affective Disorders
#4
JOURNAL ARTICLE
Kerstin Wolk, Maximilian Schielein, Julia-Tatjana Maul, Fontaine Widmayer, Kerstin Wanke, Wolfgang Fischmann, Petra Nathan, Robert Sabat
BACKGROUND: Chronic inflammatory skin diseases (CISDs) are among the most common diseases in the Western world. Current estimates of medical care for CISDs are primarily based on surveys among patients in medical care facilities and on health insurance data. AIM: Survey-based examination to what extent CISD patients in health-aware environment consider their skin disease to be controlled. METHODS: The survey of CISD patients was carried out in 2022 among the employees of a pharmaceutical company located in Germany and Switzerland...
2024: Frontiers in Medicine
#5
Sebastian Francis, Tom King, Martin P Zeidler
JAK/STAT pathway signalling is associated with both chronic inflammatory conditions such as psoriasis and haematological malignancies such as the myeloproliferative neoplasms (MPNs). Here we describe a 73yo female patient with a history of chronic plaque psoriasis, post-essential thrombocythemia myelofibrosis (MF) and a quality of life substantially impacted by both conditions. We report that 15 mg oral Methotrexate (MTX) weekly as a monotherapy is well tolerated, provides a substantial clinical improvement for both conditions and significantly improves quality of life...
2024: Frontiers in Medicine
#6
JOURNAL ARTICLE
Julia Nowowiejska, Agata Karny, Miłosz Nesterowicz, Piotr Purpurowicz, Anna Baran, Tomasz W Kaminski, Zbigniew Purpurowicz, Iwona Flisiak
INTRODUCTION: Psoriasis is one the most common skin diseases associated with a great decrease in the quality of patients' lives. METHODS: We aimed to study sexual dysfunctions in psoriatic patients using the Female Sexual Function Index (FSFI) for women and the International Index of Erectile Function (IIEF) for men via an anonymous online survey. The study included 80 psoriatic patients and 75 controls without dermatoses. RESULTS: There was a downward trend in the total IIEF score in psoriatic men compared to controls...
2024: Frontiers in Public Health
#7
JOURNAL ARTICLE
Prajakta Bule, Prashant Kadkanje, Ravikiran Kshirsagar, Eswara Rao Puppala, Vegi Ganga Modi Naidu, Naveen Chella
Psoriasis is a chronic inflammatory and proliferative skin disease that causes pathological skin changes and has a substantial impact on the quality of patient life. Apremilast was approved by the US Food and Drug Administration as an oral medication for psoriasis and is beneficial in mild to moderate conditions for chronic usage. However, 5%-7% of withdrawals were reported due to severe side effects. To address the issue, a localized drug delivery strategy via the topical route may be a viable approach. However, poor physicochemical properties make it vulnerable to passing through the skin, requiring a specialized drug delivery system to demonstrate its full potential via a topical route like lecithin organogel...
May 2024: Drug Development Research
#8
JOURNAL ARTICLE
Steven R Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadlo-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho
BACKGROUND: Ustekinumab is a safe and effective treatment for moderate-to-severe psoriasis. OBJECTIVES: To compare efficacy, safety, pharmacokinetics (PK), and immunogenicity of the proposed ustekinumab biosimilar SB17 with reference ustekinumab (UST) in subjects with moderate to severe plaque psoriasis. METHODS: In this randomized double-blind study, subjects were randomized to receive 45 mg of SB17 or UST subcutaneously at Week 0, 4, and every 12 weeks...
April 27, 2024: Journal of the American Academy of Dermatology
#9
JOURNAL ARTICLE
Ibrahim A Al-Homood, Mohammed Alajlan, Majid Alberdisi, Mohammad Alturki, Ahmed Ali Ahmed, Nancy Zakaria
INTRODUCTION: Psoriasis (PsO) is an immune-mediated chronic inflammatory disease that results in severe outcomes that impact the patient's quality of life and work productivity. We investigated the effectiveness of secukinumab in patients with chronic plaque psoriasis and psoriatic arthritis (PsA) over a 12-month period. METHODS: This was a longitudinal, retrospective study of the medical records of 81 patients with psoriasis and/or psoriatic arthritis who had been treated with secukinumab for at least 12 weeks...
April 29, 2024: Advances in Rheumatology
#10
REVIEW
Monica Dinu, Alin Laurențiu Tatu, Dorin Ioan Cocoș, Lawrence Chukwudi Nwabudike, Ana Maria Chirilov, Claudia Simona Stefan, Kamel Earar, Olimpia Dumitriu Buzia
Skin conditions are numerous and often have a major impact on patients' quality of life, and effective and safe treatment is very important. The conventional drugs used for skin diseases are usually corticosteroids and antimicrobial products that can induce various side effects, especially with long-term use, which is why researchers are studying alternatives, especially biologically active natural products. Three products caught our attention: bee venom (BV), due to reported experimental results showing anti-inflammatory, antibacterial, antiviral, antioxidant, antimycotic, and anticancer effects, Ficus carica (FC) due to its demonstrated antioxidant, antibacterial, and anti-inflammatory action, and finally Geranium essential oil (GEO), with proven antifungal, antibacterial, anti-inflammatory, and antioxidant effects...
April 10, 2024: Life
#11
MULTICENTER STUDY
Gustavo Gomes Resende, Carla Goncalves Schahin Saad, Claudia Diniz Lopes Marques, Sandra Lúcia Euzébio Ribeiro, Maria Bernadete Renoldi de Oliveira Gavi, Michel Alexandre Yazbek, Adriana de Oliveira Marinho, Rita de Cássia Menin, Manuella Lima Gomes Ochtrop, Andressa Miozzo Soares, Nara Gualberto Cavalcanti, Jamille Nascimento Carneiro, Glaucio Ricardo Werner de Castro, José Mauro Carneiro Fernandes, Elziane da Cruz Ribeiro E Souza, Corina Quental de Menezes Alvarenga, Rejane Maria Rodrigues de Abreu Vieira, Natalia Pereira Machado, Antônio Carlos Ximenes, Morgana Ohira Gazzeta, Cleandro Pires de Albuquerque, Thelma Larocca Skare, Mauro Waldemar Keiserman, Charles Lubianca Kohem, Gabriel Sarkis Benacon, Vítor Florêncio Santos Rocha, Ricardo da Cruz Lage, Olivio Brito Malheiro, Rywka Tenenbaum Medeiros Golebiovski, Thauana Luiza Oliveira, Ruben Horst Duque, Ana Carolina Londe, Marcelo de Medeiros Pinheiro, Percival Degrava Sampaio-Barros
BACKGROUND: There is a remarkable variability in the frequency of HLA-B27 positivity in patients with spondyloarthritis (SpA), which may be associated with different clinical presentations worldwide. However, there is a lack of data considering ethnicity and sex on the evaluation of the main clinical and prognostic outcomes in mixed-race populations. The aim of this study was to evaluate the frequency of HLA-B27 and its correlation with disease parameters in a large population of patients from the Brazilian Registry of Spondyloarthritis (RBE)...
April 26, 2024: Advances in Rheumatology
#12
JOURNAL ARTICLE
Ana Teixeira, Maribel Teixeira, Rita Gaio, Tiago Torres, Sofia Magina, Maria Alzira Pimenta Dinis, José Sousa-Lobo, Isabel Almeida, Miguel Peixoto, Vera Almeida
(1) Background: Psoriasis is a common chronic inflammatory skin disease with different manifestations, affecting the quality of life at social, emotional, and professional dimensions and requiring long-term treatment. This study aimed to investigate the effect of psychosocial and clinical factors on adherence to topical treatment in psoriasis. (2) Methods: Self-reported measures and weighing the medicines were used to assess adherence. Psychopathological symptoms were measured using the Brief Symptoms Inventory (BSI)...
April 12, 2024: Healthcare (Basel, Switzerland)
#13
JOURNAL ARTICLE
Won Ji Song, Hyun-Sun Yoon
Recent advances in biologic treatments have made clear skin a realistic treatment goal for psoriasis. However, clear skin may not uniformly translate to an absence of impact on patients' quality of life. This retrospective observational study aimed to elucidate the factors influencing patient-reported outcomes in patients with psoriasis who have demonstrated successful clinician-reported outcomes on using biologics. A total of 96 patients who have achieved a ≥75% improvement in Psoriasis Area and Severity Index (PASI) scores with ≥6 months of biologic treatment were included...
April 25, 2024: Journal of Dermatology
#14
JOURNAL ARTICLE
Fan Jiang, Lingyi Lu, Sihan Wang, Feng Yuan, Lu Cao, Suling Xu, Bingjiang Lin
PURPOSE: The purpose of this study was to investigate the comprehensive impact of family history of psoriasis, lesion size, disease severity, and the possibility of joint involvement on patients' quality of life(QoL). PATIENTS AND METHODS: Data from 5961 patients with psoriasis recruited from 440 hospitals throughout China were analyzed. The effects of family history of psoriasis, Body Surface Area(BSA), Psoriasis Area and Severity Index(PASI), and Psoriasis Epidemiology Screening Tool(PEST) on their Dermatology Life Quality Index(DLQI) were studied using a moderated chained mediated effects test...
2024: Clinical, Cosmetic and Investigational Dermatology
#15
JOURNAL ARTICLE
Alexander Egeberg, Jason E Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong
INTRODUCTION: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with non-systemic therapies, this post hoc analysis focused on scalp psoriasis in patients with moderate-to-severe plaque psoriasis and baseline scalp involvement. The analysis considered a holistic concept of clearance through 5 years of ixekizumab treatment...
April 22, 2024: Dermatology and Therapy
#16
JOURNAL ARTICLE
L N Gumenyuk, M Yu Kuznetsova, M B Ispiryan, U I Basnaev, N E Karakursakov
UNLABELLED: Search of new rational ways to increase the effectiveness of treatment and rehabilitation measures for patients with psoriasis vulgaris continues to be one of the urgent problems in modern clinical dermatology. OBJECTIVE: To carry out a comparative analysis of the impact of different variants of sanatorium-resort treatment (SRT) - pelotherapy and pelotherapy in combination with intravenous laser blood irradiation (ILBI) - on the level of IL-17 and TNF-a, dermatological status, psychoemotional state and quality of life (QL) assessment of patients with psoriasis vulgaris...
2024: Voprosy Kurortologii, Fizioterapii, i Lechebnoĭ Fizicheskoĭ Kultury
#17
JOURNAL ARTICLE
Alan J Kivitz, Joel M Kremer, Clarence W Legerton, Luminita Pricop, Atul Singhal
INTRODUCTION: The aim of this work is to evaluate secukinumab vs. placebo in a challenging-to-treat and smaller US patient subpopulation of the international FUTURE 2-5 studies in patients with psoriatic arthritis (PsA). METHODS: Data were pooled from US patients enrolled in the phase 3 FUTURE 2-5 studies (NCT01752634, NCT01989468, NCT02294227, and NCT02404350). Patients received secukinumab 300 or 150 mg with subcutaneous loading dose, secukinumab 150 mg without subcutaneous loading dose, or placebo...
April 16, 2024: Rheumatology and Therapy
#18
JOURNAL ARTICLE
Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
The development of flares or new-onset of immune-mediated dermatologic diseases, including psoriasis, has occurred with the worldwide spreading of the COVID-19 pandemic. We report the case of a 38-year-old woman who came to our department with a severe flare of plaque psoriasis four weeks after SARS-CoV-2 infection. Her Psoriasis Area Severity Index was 25, and her Dermatology Life Quality Index was 18. Our initial decision was to prescribe acitretin, but the patients reported adverse events. For this reason, we started risankizumab with complete skin clearance after 16 weeks...
March 12, 2024: Dermatology Reports
#19
REVIEW
C A M van Riel, C A J Michielsens, M E van Muijen, L S van der Schoot, J M P A van den Reek, E M G J de Jong
Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i) was scarce. The current review provides a literature update on the previous scoping review on the DR of all biologics, including the newest generation, with a focus on the uptake and implementation of DR in practice. The current literature search on DR revealed 14 new articles in addition to those in the previous review...
2024: Frontiers in Pharmacology
#20
JOURNAL ARTICLE
S Gerdes, R Ostendorf, A Süß, T Schadeck, F Taut, J Makuc, L Scharfenberger, S Jacobsen, N Trenkler, J Behrens, G Joks, S Tabori, D Mortazawi
BACKGROUND: G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting. OBJECTIVES: The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization. METHODS: Patients (≥18 years old) received guselkumab per routine clinical practice...
April 11, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
